Ken Herrmann spends much of his time researching Nuclear medicine, Prostate cancer, Radiology, Positron emission tomography and Internal medicine. His Nuclear medicine study combines topics in areas such as Biopsy, Somatostatin receptor and CXCR4. His research on Prostate cancer often connects related topics like Radiation treatment planning.
His work in the fields of Radiology, such as PET-CT and Gold standard, intersects with other areas such as In patient. His Positron emission tomography research integrates issues from Cancer, Predictive value of tests, Magnetic resonance imaging and Non-Hodgkin's lymphoma. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Oncology and Fluorodeoxyglucose.
His primary areas of study are Nuclear medicine, Radiology, Positron emission tomography, Internal medicine and Prostate cancer. His Nuclear medicine research is multidisciplinary, incorporating elements of Lesion, Prostatectomy and Histopathology. His work deals with themes such as Breast cancer and Lymph node, which intersect with Radiology.
Ken Herrmann focuses mostly in the field of Positron emission tomography, narrowing it down to matters related to Pathology and, in some cases, CXCR4. Ken Herrmann interconnects Gastroenterology and Oncology in the investigation of issues within Internal medicine. His studies deal with areas such as Cancer research, Radiation therapy and Radioligand as well as Prostate cancer.
Prostate cancer, Internal medicine, Nuclear medicine, Oncology and Radiology are his primary areas of study. His Prostate cancer study combines topics from a wide range of disciplines, such as PET-CT, Radiation therapy, Radionuclide therapy and Radioligand. His work on Clinical trial, Castration resistant, Retrospective cohort study and Cancer as part of general Internal medicine research is often related to In patient, thus linking different fields of science.
His study involves Positron emission tomography and Standardized uptake value, a branch of Nuclear medicine. His Positron emission tomography research is multidisciplinary, incorporating perspectives in Breast cancer and Magnetic resonance imaging. His Radiology study incorporates themes from Prospective cohort study and Lymph node.
His scientific interests lie mostly in Nuclear medicine, Prostate cancer, Internal medicine, In patient and Positron emission tomography. His work on Standardized uptake value as part of general Nuclear medicine research is frequently linked to International survey, bridging the gap between disciplines. His Prostate cancer research incorporates elements of Biomarker, PET-CT, Interquartile range and Orchiectomy.
His Internal medicine research includes themes of Gastroenterology, Oncology and Coping. His Positron emission tomography research is under the purview of Radiology. His biological study spans a wide range of topics, including Neuroimaging, Intrahepatic Cholangiocarcinoma and Limbic system.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Florian Lordick;Katja Ott;Bernd-Joachim Krause;Wolfgang A Weber.
Lancet Oncology (2007)
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.
Wolfgang P. Fendler;Wolfgang P. Fendler;Matthias Eiber;Matthias Eiber;Mohsen Beheshti;Jamshed Bomanji.
European Journal of Nuclear Medicine and Molecular Imaging (2017)
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
Katja Ott;Wolfgang A. Weber;Florian Lordick;Karen Becker.
Journal of Clinical Oncology (2006)
The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
B. J. Krause;M. Souvatzoglou;M. Tuncel;K. Herrmann.
European Journal of Nuclear Medicine and Molecular Imaging (2008)
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P Fendler;Wolfgang P Fendler;Jeremie Calais;Matthias Eiber;Matthias Eiber;Robert R Flavell.
JAMA Oncology (2019)
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Matthias Eiber;Matthias Eiber;Ken Herrmann;Jeremie Calais;Boris Hadaschik.
The Journal of Nuclear Medicine (2018)
2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy
Heiko Schöder;Ken Herrmann;Mithat Gönen;Hedvig Hricak.
Clinical Cancer Research (2005)
68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning
Jeremie Calais;Johannes Czernin;Minsong Cao;Amar U. Kishan.
The Journal of Nuclear Medicine (2018)
Comparison of Integrin αvβ3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG
Ambros J. Beer;Sylvie Lorenzen;Stephan Metz;Ken Herrmann.
The Journal of Nuclear Medicine (2008)
68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
Christina Bluemel;Markus Krebs;Bülent Polat;Fränze Linke.
Clinical Nuclear Medicine (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: